Literature DB >> 7637023

Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD.

T S McKenna1, J Lubroth, E Rieder, B Baxt, P W Mason.   

Abstract

Binding of foot-and-mouth disease virus (FMDV) to cells requires an arginine-glycine-aspartic acid (RGD) sequence in the capsid protein VP1. We have genetically engineered an FMDV in which these three amino acids have been deleted, producing a virus particle which is unable to bind to cells. Cattle vaccinated with these receptor binding site-deleted virions were protected from disease when challenged with a virulent virus, demonstrating that these RGD-deleted viruses could serve as the basis for foot-and-mouth disease vaccines safer than those currently in use. This strategy may prove useful in the development of vaccines for other viral diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7637023      PMCID: PMC189442     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

Review 1.  New observations on antigenic diversification of RNA viruses. Antigenic variation is not dependent on immune selection.

Authors:  E Domingo; J Díez; M A Martínez; J Hernández; A Holguín; B Borrego; M G Mateu
Journal:  J Gen Virol       Date:  1993-10       Impact factor: 3.891

2.  The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution.

Authors:  R Acharya; E Fry; D Stuart; G Fox; D Rowlands; F Brown
Journal:  Nature       Date:  1989-02-23       Impact factor: 49.962

3.  Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.

Authors:  B Baxt; V Vakharia; D M Moore; A J Franke; D O Morgan
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

4.  Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus.

Authors:  N Parry; G Fox; D Rowlands; F Brown; E Fry; R Acharya; D Logan; D Stuart
Journal:  Nature       Date:  1990-10-11       Impact factor: 49.962

5.  Identification of foot-and-mouth disease virus replication in vaccinated cattle by antibodies to non-structural virus proteins.

Authors:  H G Berger; O C Straub; R Ahl; M Tesar; O Marquardt
Journal:  Vaccine       Date:  1990-06       Impact factor: 3.641

6.  The effect of peptides containing the arginine-glycine-aspartic acid sequence on the adsorption of foot-and-mouth disease virus to tissue culture cells.

Authors:  B Baxt; Y Becker
Journal:  Virus Genes       Date:  1990-06       Impact factor: 2.332

7.  Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice.

Authors:  E Rieder; T Bunch; F Brown; P W Mason
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway.

Authors:  P W Mason; E Rieder; B Baxt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

9.  Structure of a major immunogenic site on foot-and-mouth disease virus.

Authors:  D Logan; R Abu-Ghazaleh; W Blakemore; S Curry; T Jackson; A King; S Lea; R Lewis; J Newman; N Parry
Journal:  Nature       Date:  1993-04-08       Impact factor: 49.962

10.  Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV.

Authors:  E Rieder; B Baxt; J Lubroth; P W Mason
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

View more
  27 in total

1.  Arginine-glycine-aspartic acid motif is critical for human parechovirus 1 entry.

Authors:  Y Boonyakiat; P J Hughes; F Ghazi; G Stanway
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 2.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine.

Authors:  G Ward; E Rieder; P W Mason
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor.

Authors:  S Neff; D Sá-Carvalho; E Rieder; P W Mason; S D Blystone; E J Brown; B Baxt
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Cell recognition by foot-and-mouth disease virus that lacks the RGD integrin-binding motif: flexibility in aphthovirus receptor usage.

Authors:  E Baranowski; C M Ruiz-Jarabo; N Sevilla; D Andreu; E Beck; E Domingo
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle.

Authors:  D Sa-Carvalho; E Rieder; B Baxt; R Rodarte; A Tanuri; P W Mason
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Analysis of a foot-and-mouth disease virus type A24 isolate containing an SGD receptor recognition site in vitro and its pathogenesis in cattle.

Authors:  Elizabeth Rieder; Tina Henry; Hernando Duque; Barry Baxt
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  Interactions of foot-and-mouth disease virus with soluble bovine alphaVbeta3 and alphaVbeta6 integrins.

Authors:  Hernando Duque; Michael LaRocco; William T Golde; Barry Baxt
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Propagation of an attenuated virus by design: engineering a novel receptor for a noninfectious foot-and-mouth disease virus.

Authors:  E Rieder; A Berinstein; B Baxt; A Kang; P W Mason
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

10.  Attenuated foot-and-mouth disease virus RNA carrying a deletion in the 3' noncoding region can elicit immunity in swine.

Authors:  Miguel Rodríguez Pulido; Francisco Sobrino; Belén Borrego; Margarita Sáiz
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.